Social Media Ideas for Fibrobiologics

FibroBiologics Announces Grant of European Patent for Methods of Enhancing Fibroblast Therapeutic Activity

Chronic lower back pain is one of the most common and costly medical conditions, and degeneration of the intervertebral discs is a frequent underlying cause.

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Dise...

HOUSTON, Oct. 19, 2026 /PRNewswire/ — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+…

FibroBiologics, Inc. (FBLG) Discusses Strategy and Clinical Progress in Fibroblast-Based Cell Therapies for Chronic Dise...

FibroBiologics Announces Issuance of New U.S. Patent for the Therapeutic Use of Fibroblasts in Wound Healing

Newly issued patent covers topical administration of 3D spheroid fibroblasts and fibroblast-derived materials to treat and accelerate the healing of wounds.

FibroBiologics Presents Preclinical Data on Fibroblast Spheroid-Derived Chondrocyte Spheroids for Degenerative Disc Dise...

FSdC Spheroids preserved disc height better than any other fibroblast-based approach tested in a 12-week rabbit model of degenerative disc disease.

FibroBiologics Appoints Leigh Steinberg to Board of Directors

Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, Aug. 24, 2026 /PRNewswire/…

Biocomposites to host industry symposium and present new STIMULAN® data at EBJIS-MSIS 2026

KEELE, United Kingdom, Sept. 09, 2026 (GLOBE NEWSWIRE) — Biocomposites, an international medical devices company that engineers, manufactures…

FDA approves Atebrioz for fibrodysplasia ossificans progressiva

Editor’s note: This is a developing story. Please check back soon for updates.The FDA approved zilurgisertib tablets for the reduction of heterotopic ossification among patients ag...

BODYWELLE Announces Exclusive Use of ZEO ScientifiX Biologics for Pain, Joints, and Wound Care Treatments

The Miami Beach practice now uses quantified stem cell and extracellular vesicle products, along with an autologous option derived from the patient's own platelets.

Applied Biologics Publishes New Translational Research Demonstrating Ligament Regeneration with XWRAP®-Based Biologic Au...

SCOTTSDALE, Ariz., Sept. 30, 2026 (GLOBE NEWSWIRE) — Applied Biologics, a biopharmaceutical company advancing novel therapies for serious…

PharmaNest and Mediar Therapeutics Collaborate to Quantify ECM and Fibrosis Remodeling in the EncompaSSc Phase 2 Trial o...

Companies to use AI-enabled digital pathology and spatial single-fiber analysis to characterize the mechanistic effects of MTX-474 in systemic sclerosis

DiFusion to Define Therapeutic Biomaterials Category at NASS 2026

Red Theater presentation will distinguish conventional biotolerable implants from materials deliberately engineered to influence the host response and participate in healing

New Antibody Targets BAMBI to Rewire Immune Cells in Psoriatic Arthritis

Spanish researchers have developed a humanized monoclonal antibody, hB101.37, that inhibits the BAMBI pseudoreceptor and rebalances T cell immunity, showing therapeutic efficacy an...

BioLab Holdings Launches EmeraNovaâ„¢ to Advance the Future of Tissue Restoration

Expanded vision reflects focus beyond wound care to advancing innovation across the full tissue restoration journey PHOENIX, October…

Consano Bio to Highlight C-1101, Its Potential First-in-Class Disease-Modifying Therapeutic for Chronic Sciatica, at Upc...

Mirum Pharma Pill Lands FDA Approval for Ultra-Rare Bone Growth Disorder

Mirum Pharmaceuticals’ Atebrioz is the third FDA-approved drug for fibrodysplasia ossificans progressiva (FOP), but it brings advantages over the two other products for this rare d...

Zenas BioPharma, Inc. (ZBIO) Discusses Obexelimab Prelaunch Strategy and Commercial Opportunity in IgG4-Related Disease...

FDA extends review of Capricor cell therapy; Pain drug startup to go public

The agency is now reviewing an updated application for deramiocel with a “refined” indication. Elsewhere, a startup co-founded by Vivek Ramaswamy is taking a speedy path to the pub...

UK’s MHRA Accepts Biosplice’s Application for Lorecivivint (LOR) in Knee Osteoarthritis and Begins Assessment

LOR, the first approval-stage drug candidate with disease-modifying potential for osteoarthritis, is now under assessment in the United…

Bone Biologics Expands Trial Sites

Addition of three sites strengthens expectation to complete enrollment by year-end 2026 BURLINGTON, MA, Sept. 08, 2026 (GLOBE…

Lung Fibrosis Drug Lowers Biological Age Estimates

Six different aging clocks detected younger blood protein profiles in patients taking the experimental lung-fibrosis drug rentosertib. This suggests possible anti-aging effects, bu...

BridgeBio

BridgeBio Anonymous (not verified) Tue, 10/13/2026 - 07:11 field_thread_url https://cafepharma.com/boards/threads/bridgebio.698762/ boar...

Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds

Amgen’s dazodalibep led to statistically significant and clinically meaningful results, according to preliminary Phase 3 results in Sjögren’s disease. This fusion protein could com...

CovationBio Introduces Sorona Elasterell-p Fiber

Newark, Del.-based Covation Biomaterials LLC, doing business as CovationBio, has introduced Sorona elasterell-p fiber, its first branded fiber and first U.S.-produced bicomponent s...